Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to -$415000.0.

  • Barinthus Biotherapeutics' Share-based Compensation fell 13627.62% to -$415000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $527000.0, marking a year-over-year decrease of 8888.19%. This contributed to the annual value of $4.7 million for FY2024, which is 684.47% down from last year.
  • As of Q3 2025, Barinthus Biotherapeutics' Share-based Compensation stood at -$415000.0, which was down 13627.62% from -$281000.0 recorded in Q2 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Share-based Compensation peaked at $8.7 million during Q2 2021, and registered a low of -$415000.0 during Q3 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' median Share-based Compensation value was $1.2 million (recorded in 2024), while the average stood at $1.9 million.
  • In the last 5 years, Barinthus Biotherapeutics' Share-based Compensation skyrocketed by 209090.91% in 2021 and then crashed by 13627.62% in 2025.
  • Quarter analysis of 5 years shows Barinthus Biotherapeutics' Share-based Compensation stood at $3.6 million in 2021, then plummeted by 42.99% to $2.0 million in 2022, then tumbled by 61.49% to $786000.0 in 2023, then fell by 3.94% to $755000.0 in 2024, then plummeted by 154.97% to -$415000.0 in 2025.
  • Its last three reported values are -$415000.0 in Q3 2025, -$281000.0 for Q2 2025, and $468000.0 during Q1 2025.